Room for Growth in Millionaire Stocks
Just because a stock has already made substantial gains doesn’t mean it’s out of potential for further growth. Take Alphabet and Eli Lilly. Both companies have shown remarkable profits over the last two decades. If someone had invested $50,000 in either back in 2006, it would have transformed into over $1 million today. Yet, these industry leaders still have significant opportunities for disruption in the market in the coming years. This is why investors are still drawn to Alphabet and Eli Lilly.
1. Alphabet
Alphabet is widely recognized for its search engine, Google, which maintains a dominant position. This advantage is likely to keep driving sales in the future. The company is leveraging artificial intelligence (AI) to enhance search functions, boost engagement, and increase ad revenues. Moreover, Alphabet’s business extends well beyond its initial offerings. In the decade ahead, the company could seize various growth opportunities that might yield impressive returns.
One area of interest is cloud computing, which has been rapidly expanding. Some investors express concern about the required capital investments, but personally, I believe Alphabet is well-positioned. The company stands to benefit greatly from the evolving AI sector, with its potential to generate significant advantages.
Additionally, Alphabet leads in streaming via YouTube, which is often underrated. With streaming viewership projected to rise significantly, Alphabet is set to capitalize on this trend. YouTube’s strong brand, extensive user base, and robust network effects should help it remain a key player in this space.
Then there’s Alphabet’s ambitious self-driving car project through Waymo. With operations in several U.S. cities, Waymo has achieved Level 4 autonomy in its vehicles. While competition is growing, Alphabet’s established partnerships, notably with Uber, give it a substantial edge.
The increasing acceptance of self-driving cars in the next decade opens new avenues for Alphabet, potentially transforming its business model. To sum it up: this company is a frontrunner in multiple fast-growing sectors and possesses strong barriers to entry, alongside a culture of innovation. All these elements could lead to even greater profits by 2036.
2. Eli Lilly
For investors looking at Eli Lilly, the company’s strong foothold in the weight loss market is a major draw—and there’s good reason for that. They have made significant progress, and further advancements seem likely. However, the pharmaceutical industry is cyclical. Clinical and regulatory developments are crucial for boosting stock valuations, but setbacks and patent expirations can reverse gains. Could Eli Lilly disrupt this pattern?
That seems to be the goal. The company is pouring resources into AI-driven drug discovery, which, if successful, could massively impact its operations. By reducing both the time and cost involved in developing new drugs, Eli Lilly can deliver medications to patients more rapidly and maximize their market presence before patents expire. This could translate to billions in extra revenue for certain products.
With this approach, Eli Lilly may also enjoy more time to develop fresh drugs before losing patent protection on existing ones, potentially altering the conventional cycle seen in drug companies and enhancing their overall value. While success isn’t guaranteed, the promising AI initiatives, their current lineup of drugs looking to set industry benchmarks, and a diverse pipeline all suggest a bright future ahead for Eli Lilly. Although the stock has lagged behind the broader market since start of 2026, those planning to hold their Eli Lilly shares through 2036 may still consider entering a position.
